Endometrial cancer, antibody and chemotherapy reduce risk of death by 31%

2024-03-21 17:10:54

Immuno-oncology therapy combining the monoclonal antibody dostarlimab and chemotherapy was effective in reducing the risk of death by 31% and improving median overall survival by 16.4 months in patients with advanced or advanced primary endometrial cancer. recurring. This is highlighted by the results of the Ruby 1 and 2 clinical trials, presented by GSK as a preview in the plenary session of the Annual Meeting of the Society of Gynecologic Oncology on Women’s Cancer in San Diego and illustrated today to the Italian press with a press conference in Milan.